| Company type | Incorporated |
|---|---|
| Industry | Insurance |
| Founded | 2006 |
| Founder | Robert Clements, John Clements |
Key people | Kevin Kelley |
Ironshore Inc. provides broker-sourced specialty property and casualty insurance coverages[1] for varying risks on a global basis through its platforms in Australia, Bermuda, Canada, Ireland, Singapore, the United States and the United Kingdom.[2][3][4][5] On December 5, 2016, it was announced that Ironshore will be sold to Liberty Mutual in a $3 billion transaction.[6]
The company was founded in 2006, with more than $1 billion in equity, by Robert Clements and his son John Clements, two long-time insurance investors.[7][8][9]
Ironshore named Kevin Kelley as CEO in December 2008.[10][11][12][13] Kelley had been the longtime CEO of Lexington Insurance, which became the largest excess and surplus lines insurer in the world under his leadership.[14] Shaun Kelly resigned as president and Chief Operating Officer of Lexington and was appointed chief executive officer of U.S. Operations for Ironshore.[15] During 2015, Ironshore acquired Dubai-based MGA, Visionary underwriting Agency Ltd, a Lloyd's Coverholders founded in 2010 by David Austin.[citation needed]
The company's product lines include Aviation, Environmental,[16][17] IronBuilt, IronHealth,[18] IronPro, Marine Re, Personal Lines,[19] Political Risk,[20] Ironshore Programs,[21] and U.S. Property and Specialty Casualty.[22]
The Ironshore group of companies is rated A (Excellent) by A.M. Best with a Financial Size Category of XIV. Ironshore’s Pembroke Syndicate 4000 operates within Lloyd’s with a market rating of A (Excellent) from A.M. Best and A+ from both Standard and Poor’s and Fitch Group. A.M. Best announced in 2012 a revised rating outlook to "Positive" for Ironshore and its subsidiaries.[23][24]
On 29 June 2020, Ironshore Pharmaceuticals Inc. ('Ironshore'), a wholly owned affiliate of Highland Therapeutics Inc., confirmed the publication in the Field of Clinical Psychopharmacology of an original paper outlining a concept that could promote the dose optimisation of JORNAY PM® (methylphenidate HCl) extended-release capsules CII. In August 2018, the US Food and Drug Administration (FDA) licensed JORNAY PM to treat ADHD in children 6 years of age and older.[25]